Wasatch Advisors Inc. increased its position in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 26.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,437,908 shares of the biopharmaceutical company’s stock after acquiring an additional 1,359,170 shares during the quarter. Wasatch Advisors Inc. owned approximately 0.06% of Sangamo Therapeutics worth $61,418,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Sangamo Therapeutics by 29.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,787 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 1,552 shares during the last quarter. Pearl River Capital LLC acquired a new position in Sangamo Therapeutics in the first quarter valued at about $94,000. Oppenheimer Asset Management Inc. acquired a new position in Sangamo Therapeutics in the fourth quarter valued at about $102,000. Raymond James Financial Services Advisors Inc. lifted its position in Sangamo Therapeutics by 10.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 12,030 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 1,100 shares during the last quarter. Finally, Merriman Wealth Management LLC acquired a new position in Sangamo Therapeutics in the fourth quarter valued at about $119,000. 56.64% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:SGMO traded down $0.37 on Thursday, reaching $9.37. 19,127 shares of the company’s stock were exchanged, compared to its average volume of 1,486,076. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.98 and a quick ratio of 3.98. The firm has a market capitalization of $1.09 billion, a PE ratio of -13.50 and a beta of 2.89. Sangamo Therapeutics Inc has a 52-week low of $6.26 and a 52-week high of $19.25.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.14). The business had revenue of $8.07 million for the quarter, compared to analysts’ expectations of $27.21 million. Sangamo Therapeutics had a negative return on equity of 24.67% and a negative net margin of 113.03%. Analysts expect that Sangamo Therapeutics Inc will post -1.39 EPS for the current fiscal year.

In related news, CFO Kathy Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $10.00, for a total transaction of $50,000.00. Following the sale, the chief financial officer now directly owns 30,512 shares in the company, valued at $305,120. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 20,000 shares of company stock worth $210,550 over the last 90 days. Insiders own 1.30% of the company’s stock.

A number of research firms have commented on SGMO. Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research report on Tuesday, May 14th. ValuEngine lowered shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, February 10th. Finally, BidaskClub upgraded shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Sangamo Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $16.00.

ILLEGAL ACTIVITY WARNING: “Wasatch Advisors Inc. Purchases 1,359,170 Shares of Sangamo Therapeutics Inc (SGMO)” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://theolympiareport.com/2019/05/23/wasatch-advisors-inc-purchases-1359170-shares-of-sangamo-therapeutics-inc-sgmo.html.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Featured Story: What are the most popular ETFs

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.